The use of remote patient monitoring (RPM) and decentralised clinical trials (DCTs) have surged as the industry started using these strategies to tackle the COVID-19-induced clinical trial disruptions.
GlobalData conducted a survey to identify how the pharmaceutical and healthcare industry is addressing clinical trial disruptions amid the pandemic.
Addressing Clinical Trial Disruptions Related to the COVID-19 Outbreak
According to the survey results, 17% of the respondents adopted RPM to address clinical trial disruptions, while another 15% intend to switch to DCTs.
Approximately 14% voted for remote site initiation visits, while 13% of the companies asked research staff to work remotely.
Direct-to-patient (DTP) drug delivery was selected by 11% of the respondents.
Among the respondents, 9% halted screening and/ or enrolment for all clinical trials due to the pandemic situation and another 7% completely ceased opening any new trials.
Around 7% of the surveyed companies prioritised enrolment for certain clinical trials.
The remaining 7% respondents implemented remote safety lab collections.
The analysis is based on responses received for the Coronavirus Disease 2019 (COVID-19) Sector Impact: The COVID-19 Pandemic Impact on Clinical Trials survey conducted by GlobalData between 04 June and 22 June 2020.
